Related Experiment Video
Updated: Aug 25, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
The pharmacokinetics of single high doses of dexamethasone in cancer patients
M E Brady1, G P Sartiano, S L Rosenblum
1College of Pharmacy, University of South Carolina, Columbia.
Abstract:
We have given single high doses of dexamethasone phosphate by intravenous infusion as an antiemetic to 15 cancer patients receiving regimens containing cisplatin and/or doxorubicin. The patients received graded doses of dexamethasone phosphate, in the range 40-200 mg, dependent upon nausea and vomiting scores, during up to three consecutive cycles of cancer chemotherapy. Plasma and urine concentrations of dexamethasone (dexamethasone alcohol) were measured by HPLC. The plasma concentration - time data were described by an open two-compartment model. The pharmacokinetic variables were independent of the dose of dexamethasone over the range studied. The terminal half-time was 4.0 +/- 0.4 h and the total body clearance was 3.5 +/- 0.4 ml X min-1 X kg-1. The volume of the central compartment and the total apparent volume of distribution were 0.23 +/- 0.03 and 1.0 +/- 0.1 l X kg-1 respectively. Approximately 8% of the dose was excreted into the urine as dexamethasone.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:00The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Dosage Regimen: Multiple Oral Dosage
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship